Re-biopsy in Advanced NSCLC after First Line Treatment: Feasibility and Clinical Utility

M. Frank (Naestved, Denmark), U. Bodtger (Naestved, Denmark), A. Høegholm (Naestved, Denmark), I. Stamp (Naestved, Denmark), J. Gehl (Naestved, Denmark)

Source: Virtual Congress 2020 – Novelties in interventional pulmonology: expanding horizons
Session: Novelties in interventional pulmonology: expanding horizons
Session type: Oral Presentation
Number: 5125
Disease area: Thoracic oncology

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Frank (Naestved, Denmark), U. Bodtger (Naestved, Denmark), A. Høegholm (Naestved, Denmark), I. Stamp (Naestved, Denmark), J. Gehl (Naestved, Denmark). Re-biopsy in Advanced NSCLC after First Line Treatment: Feasibility and Clinical Utility. 5125

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: